Abstract:Abstract Hepatocellular carcinoma (HCC) is the prevailing subtype of hepatocellular malignancy. While previous investigations have evidenced a robust link with programmed cell death (PCD) and tumorigenesis, a comprehensive inquiry targeting the relationship between multiple PCDs and HCC remains scant. Our aim was to develop a predictive model for different PCD patterns in order to investigate their impact on survival rates, prognosis and drug response rates in HCC patients. We performed functional annotation and pathway analysis on identified PCD‐related genes (PCDRGs) using multiple bioinformatics tools. The prognostic value of these PCDRGs was verified through a dataset obtained from GEO. Consensus clustering analysis was utilized to elucidate the correlation between diverse PCD clusters and pertinent clinical characteristics. To comprehensively uncover the distinct PCD regulatory patterns, our analysis integrated gene expression profiling, immune cell infiltration and enrichment analysis. To predict survival differences in HCC patients, we established a PCD model. To enhance the clinical applicability for the model, we developed a highly accurate nomogram. To address the treatment of HCC, we identified several promising chemotherapeutic agents and novel targeted drugs. These drugs may be effective in treating HCC and could improve patient outcomes. To develop a cell death feature for HCC patients, we conducted an analysis of 12 different PCD mechanisms using eligible data obtained from public databases. Through this analysis, we were able to identify 1254 PCDRGs likely to contribute to cell death on HCC. Further analysis of 1254 PCDRGs identified 37 genes with prognostic value in HCC patients. These genes were then categorized into two PCD clusters A and B. The categorization was based on the expression patterns of the genes in the different clusters. Patients in PCD cluster B had better survival probabilities. This suggests that PCD mechanisms, as represented by the genes in cluster B, may have a protective effect against HCC progression. Furthermore, the expression of PCDRGs was significantly higher in PCD cluster A, indicating that this cluster may be more closely associated with PCD mechanisms. Furthermore, our observations indicate that patients exhibiting elevated tumour mutation burden (TMB) are at an augmented risk of mortality, in comparison to those displaying low TMB and low‐risk statuses, who are more likely to experience prolonged survival. In addition, we have investigated the potential distinctions in the susceptibility of diverse risk cohorts towards emerging targeted therapies, designed for the treatment of HCC. Moreover, our investigation has shown that AZD2014, SB505124, LJI308 and OSI‐207 show a greater efficacy in patients in the low‐risk category. Conversely, for the high‐risk group patients, PD173074, ZM447439 and CZC24832 exhibit a stronger response. Our findings suggest that the identification of risk groups and personalized treatment selection could lead to better clinical outcomes for patients with HCC. Furthermore, significant heterogeneity in clinical response to ICI therapy was observed among HCC patients with varying PCD expression patterns. This novel discovery underscores the prospective usefulness of these expression patterns as prognostic indicators for HCC patients and may aid in tailoring targeted treatment for those of distinct risk strata. Our investigation introduces a novel prognostic model for HCC that integrates diverse PCD expression patterns. This innovative model provides a novel approach for forecasting prognosis and assessing drug sensitivity in HCC patients, driving a more personalized and efficacious treatment paradigm, elevating clinical outcomes. Nonetheless, additional research endeavours are required to confirm the model's precision and assess its potential to inform clinical decision‐making for HCC patients.

Multilayered insights: a machine learning approach for personalized prognostic assessment in hepatocellular carcinoma

Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden

Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma

Development And Validation Of A Prognostic And Immunotherapeutically Relevant Model In Hepatocellular Carcinoma

Novel prognostic signature for hepatocellular carcinoma using a comprehensive machine learning framework to predict prognosis and guide treatment

Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma

A Novel Prognostic Model for Predicting Patient Survival and Immunotherapy Responsiveness in Hepatocellular Carcinoma: Insights into the Involvement of T-cell Proliferation.

Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma

Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma

A Prognostic Model Based on Seven Immune-Related Genes Predicts the Overall Survival of Patients with Hepatocellular Carcinoma

Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma

Identification of a Cancer Stemness Driven Prognostic Model and Therapeutic Drug Targets by Machine Learning in Hepatocellular Carcinoma

Prognostic modeling of hepatocellular carcinoma based on T-cell proliferation regulators: a bioinformatics approach

Risk Predictive Model Based on Three DDR-Related Genes for Predicting Prognosis, Therapeutic Sensitivity, and Tumor Microenvironment in Hepatocellular Carcinoma

A Novel Prognostic Model Based on Immunogenic Cell Death-Related Genes for Improved Risk Stratification in Hepatocellular Carcinoma Patients.

Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma

The cell death‐related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma

A novel risk scoring system predicts overall survival of hepatocellular carcinoma using Cox proportional hazards machine learning method

Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes

Identification and Analysis of DNA Methylation-Driven Signatures for Prognostic and Immune Microenvironments Evaluation in Hepatocellular Carcinoma

Identification of the Cuproptosis-Related Molecular Subtypes and an Immunotherapy Prognostic Model in Hepatocellular Carcinoma